A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

NCT04251026 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Mucopolysaccharidosis II

Interventions

DRUG: tividenofusp alfa

Sponsor

Denali Therapeutics Inc.